Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVIIITY: Impact of efanesoctocog alfa (ALTUVIIIO) on goal attainment and physical activity in Hemophilia A
jRCT1031250136Completed
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoints: Proportion of total goals achieved, Proportion of patients with +2 or +1 on at least one goal and 4 more. Started May 2025; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT1031250136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250136.